GEN Exclusives

More »

GEN News Highlights

More »
Aug 22, 2007

Med Discovery and Draximage Combine Techniques

  • Med Discovery and Draximage are collaborating to explore the combination of the former’s targeted protein therapeutics with the latter’s radiopharmaceutical background in the therapeutic and diagnostics field.

    Med Discovery reports that its preclinical candidates are potential therapeutic agents for prostate cancer as well as other cancers. This partnership provides initially for the radiolabeling of certain proteins to assess the enhancement of their action and their capability to detect microtumors.

    The proteins will be produced at Med Discovery in Switzerland and radiolabeled by Draximage in Canada.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

Value-Pricing Cancer Drugs

Do you think all new cancer drugs awaiting approval should undergo value-pricing?

More »